Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Pumitamig shows strong efficacy in first-line non-small cell lung cancer in Phase 2 ROSETTA Lung-02 trial
BNTX
$91.90
-$0.09 -0.10%

Pumitamig shows strong efficacy in first-line non-small cell lung cancer in Phase 2 ROSETTA Lung-02 trial

Company Fundamentals
30 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 results for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, combined with chemotherapy in untreated advanced non-small cell lung cancer (NSCLC). The ROSETTA Lung-02 trial showed high confirmed objective response rates across non-squamous and squamous NSCLC subtypes and all PD-L1 expression levels, with a manageable safety profile. Pumitamig is advancing in multiple global Phase 3 trials aiming to improve outcomes for a broad range of NSCLC patients. These results highlight pumitamig's potential to become a new standard of care in NSCLC treatment.

More News (BNTX)

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App